TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Chugai Pharmaceutical Co ( (JP:4519) ).
Chugai Pharmaceutical Co., Ltd. has entered into a collaboration and license agreement with Rani Therapeutics to develop and commercialize an oral formulation using Rani’s RaniPill® technology and Chugai’s rare disease antibody. This partnership aims to transform biologics delivery, traditionally limited to injections, into oral therapies, enhancing patient convenience and adherence. The agreement includes a potential deal value of over $1 billion if all options are exercised, though it is not expected to impact Chugai’s financial forecast for 2025.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7879.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company known for its world-class drug discovery capabilities, including proprietary antibody engineering technologies. It focuses on creating innovative pharmaceutical products to address unmet medical needs and is a significant member of the Roche Group.
YTD Price Performance: -0.04%
Average Trading Volume: 3,693,293
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen11314.2B
Learn more about 4519 stock on TipRanks’ Stock Analysis page.